ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03105336
Recruitment Status : Recruiting
First Posted : April 7, 2017
Last Update Posted : August 3, 2018
Sponsor:
Information provided by (Responsible Party):
Kite, A Gilead Company

Brief Summary:
This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.

Condition or disease Intervention/treatment Phase
Follicular Lymphoma Marginal Zone Lymphoma Indolent Non-Hodgkin Lymphoma Biological: axicabtagene ciloleucel Phase 2

Detailed Description:

This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.

All enrolled subjects will be screened for eligibility then will undergo leukapheresis to collect white blood cells for manufacturing. In preparation for the infusion with axicabtagene ciloleucel, subjects will undergo conditioning chemotherapy with cyclophosphamide and fludarabine for 3 days to help the study treatment be effective. After the product is manufactured and conditioning chemotherapy period is complete, subjects will be infused with axicabtagene ciloleucel and then monitored in a hospital for a minimum of 7 days. Subjects will be followed by their study doctor for continued monitoring of the safety and effectiveness of the study treatment for approximately 3 months after receiving treatment and then will be followed for safety for up to an additional 3 ½ years.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Actual Study Start Date : May 10, 2017
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : October 2033


Arm Intervention/treatment
Experimental: axicabtagene ciloleucel Biological: axicabtagene ciloleucel
A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.




Primary Outcome Measures :
  1. Objective response rate [ Time Frame: 5 years ]
    Complete response (CR) + partial response (PR) per the Lugano Classiciation (Cheson et al, 2004).


Secondary Outcome Measures :
  1. CR Rate [ Time Frame: 5 years ]
    CRR is defined as the incidence of CR as best response to treatment by the Lugano Classification (Cheson et al, 2014)

  2. DOR [ Time Frame: 5 years ]
    DOR is defined only for subjects who experience an objective response and is the time from the first objective response to disease progression per (Cheson et al, 2014) or disease-related death, whichever comes first.

  3. PFS [ Time Frame: 5 years ]
    PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per (Cheson et al, 2014) or death from any cause.

  4. Safety [ Time Frame: 5 years ]
    Incidences of Aes and clinically significant changes in lab values.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1) Subject has [follicular lymphoma that has progressed within 24 months of first diagnosis and treatment with combination chemoimmunotherapy] (e.g. R-bendamustine, R-CHOP) OR Progression of iNHL within 6 months of completion of second or later line therapy containing both an anti-CD20 antibody and alkylating agent OR Progression of iNHL at any point following autologous transplantation.

    2) Subject has [measurable disease].

    3) Subject has no known presence or history of CNS involvement by lymphoma.

    4) If subject is on conventional systemic therapy or systemic inhibitory/stimulatory immune checkpoint therapy, subject is able to stop conventional therapy 2 weeks or 5 half-lives, whichever is shorter, or immune checkpoint therapy 3 half-lives prior to planned leukapheresis.

    5) Subject has ECOG performance status of 0-1 and adequate renal, hepatic, pulmonary, and cardiac function

    6) Subject is not pregnant or breastfeeding (female subjects only) and is willing to use birth control from the time of consent through 6 months following CAR T cell infusion (both male and female subjects).B24

Exclusion Criteria:

  • 1) Transformed FL

    2) Small lymphocytic lymphoma

    3) Histological Grade 3b FL

    4) Subject will have undergone autologous transplant within 6 weeks of planned leukapheresis or has undergone allogeneic transplant.

    5) Subject has evidence of involvement of the heart by lymphoma or requirement for urgent therapy due to ongoing or impending oncologic emergency (e.g. mass effect, tumor lysis syndrome, etc.)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03105336


Contacts
Contact: Medical Information 844-454-KITE medinfo@kitepharma.com

Locations
United States, Arizona
Banner MD Anderson Cancer Center Recruiting
Gilbert, Arizona, United States, 85234
Contact: Andrea Winkle    480-256-3421    andrea.winkle@bannerhealth.com   
Principal Investigator: Javier Munoz, MD         
United States, California
USC Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Kevin Kelly, MD    323-865-3828    kevin.kelly@med.usc.edu   
Principal Investigator: Kevin Kelly, MD         
University of California Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Sven de Vos, MD, PhD    310-267-2756    devos@mednet.ucla.edu   
Principal Investigator: Sven de Vos, MD, PhD         
United States, District of Columbia
Georgetown Lombardi Comprehensive Cancer Center Recruiting
Washington, District of Columbia, United States, 20057
Contact: Pashna Munshi, MD    202-444-1212    pashna.n.munshi@gunet.georgetown.edu   
Principal Investigator: Pashna Munshi, MD         
United States, Florida
University of Miami Hospital and Clinics Recruiting
Miami, Florida, United States, 33136
Contact: Nathalie Luis    305-243-7648    nluis@med.miami.edu   
Principal Investigator: Joseph Rosenblatt, MD         
H Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Matthew Scott    813-745-7227    matthew.scott@moffitt.org   
Principal Investigator: Julio Chavez, MD         
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Krystle Benedict    617-582-8713    Krystle_Benedict@dfci.harvard.edu   
Principal Investigator: Caron Jacobson, MD         
United States, New York
University of Rochester Medical Center (URMC) Recruiting
Rochester, New York, United States, 14642
Contact: Erin Enfield    585-276-4404    erin_enfield@urmc.rochester.edu   
Principal Investigator: Carla Casulo, MD         
United States, Ohio
Ohio State University Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Nicole Szuminski    614-688-9796    nicole.szuminski@osumc.edu   
Principal Investigator: Basem William, MD         
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111-2497
Contact: Elisabeth Giraud       Elisabeth.Giraud@fccc.edu   
Contact: Laura McIntyre       Laura.McIntyre@fccc.edu   
Principal Investigator: Henry Fung, MD         
UPMC Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Linda Fukas    412-623-6037    fukaslj@upmc.edu   
Principal Investigator: Alison Sehgal, MD         
United States, Tennessee
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Contact: Ask Sarah    615-339-4214    asksarah@sarahcannon.com   
Principal Investigator: Ian Flinn, MD, PhD         
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Delia Darst    615-343-7190    delia.h.darst@vumc.org   
Principal Investigator: Olalekan Oluwole, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Liliana Vallejo    713-563-4167    lnvallejo@mdanderson.org   
Contact: Sherry Adkins    713-745-3035    sadkins@mdanderson.org   
Principal Investigator: Sattva Neelapu, MD         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Contact: Immunotherapy Trials Intake    206-606-4668    immunotherapy@seattlecca.org   
Principal Investigator: David Maloney, MD, PhD         
Sponsors and Collaborators
Kite, A Gilead Company
Investigators
Study Director: Wayne Godfrey, MD, MS Kite, A Gilead Company

Responsible Party: Kite, A Gilead Company
ClinicalTrials.gov Identifier: NCT03105336     History of Changes
Other Study ID Numbers: KTE-C19-105
First Posted: April 7, 2017    Key Record Dates
Last Update Posted: August 3, 2018
Last Verified: August 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell, Marginal Zone
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell